Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFW NASDAQ:KLDO NASDAQ:NMTR NASDAQ:ONCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.20-6.3%$0.10$0.00▼$0.62N/AN/A501,334 shs243,445 shsKLDOKaleido Biosciences$0.00$0.00▼$0.07$4K-0.0611,132 shsN/ANMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs15 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences0.00%-22.30%+1,664.06%+1,992.66%+2,100.53%KLDOKaleido Biosciences0.00%-99.00%0.00%0.00%0.00%NMTR9 Meters Biopharma0.00%0.00%-99.72%-99.72%-81.82%ONCSOncoSec Medical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/AKLDOKaleido Biosciences 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/AONCSOncoSec Medical 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AKLDOKaleido Biosciences$1.10M0.00N/AN/AN/ANaNNMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/ANMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNFW180 Life SciencesN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/ANMTR9 Meters BiopharmaN/A0.590.59ONCSOncoSec MedicalN/A0.890.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/AKLDOKaleido Biosciences81.56%NMTR9 Meters Biopharma22.34%ONCSOncoSec Medical8.69%Insider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/AKLDOKaleido Biosciences9.00%NMTR9 Meters Biopharma2.40%ONCSOncoSec Medical1.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableKLDOKaleido Biosciences8042.62 million38.79 millionNot OptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataONCSOncoSec Medical404.55 million4.49 millionNot OptionableONCS, NMTR, KLDO, and ATNFW HeadlinesRecent News About These CompaniesPVCT Provectus Biopharmaceuticals, Inc.August 25, 2024 | seekingalpha.comIs OncoSec Medical Inc (ONCSQ) Stock a Good Investment?June 29, 2023 | aaii.comAONCS - OncoSec Medical IncorporatedJune 24, 2023 | finance.yahoo.com0 analysts rank ONCS stock as an OverweightJune 23, 2023 | knoxdaily.comKWhy Is OncoSec Medical (ONCS) Stock Up 100% Today?June 23, 2023 | markets.businessinsider.comWhy John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJune 15, 2023 | msn.comWhy Is OncoSec Medical (ONCS) Stock Down 48% Today?June 15, 2023 | msn.comOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 18, 2023 | finance.yahoo.comOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockMay 16, 2023 | msn.comOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 16, 2023 | finance.yahoo.comOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programMay 16, 2023 | finance.yahoo.comOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL ProgramApril 27, 2023 | finance.yahoo.comOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 11, 2023 | finance.yahoo.comWhy OncoSec Medical Shares Are Soaring TodayApril 10, 2023 | msn.comOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 10, 2023 | finance.yahoo.comOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket TradingApril 6, 2023 | benzinga.comOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting StudyApril 3, 2023 | finance.yahoo.comOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialApril 3, 2023 | msn.comOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 TreatmentApril 3, 2023 | finance.yahoo.comOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%March 1, 2023 | marketwatch.comMedia Sentiment Over TimeONCS, NMTR, KLDO, and ATNFW Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.20 -0.01 (-6.32%) As of 09/2/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Kaleido Biosciences NASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.OncoSec Medical NASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
